Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T-cell immune response
- PMID: 16872283
- DOI: 10.1111/j.1600-0684.2006.00179.x
Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T-cell immune response
Erratum in
- J Med Primatol. 2007 Feb;36(1):55. Watkins, David I [removed]
Abstract
In the present era of increasing resistance of human immunodeficiency virus (HIV) to antiviral drugs, exploration of adjunct therapies directed at immune responses in combination with antiretroviral drugs may be of value for the treatment of acquired immunodeficiency syndrome. In this study, we designed a model for immune therapy using SIVmac251 infection in rhesus macaques. We explored the outcomes of primary infection on viral loads and the resulting T-cell immune responses in primates. The SIV-infected rhesus macaque model exhibited features similar to those observed in HIV-1 infection of humans. Major histocompatibility complex (MHC) segregation with viral loads were found to associate with viral containment and hence the duration of the disease-free latency period. Thus a better understanding of the relative roles of MHC class I allele in control of viral replication may provide important information for prophylactic or therapeutic vaccine designs. Mamu-A01 is significantly associated with higher immune response and control of viral replication. This allele is frequent in rhesus macaques of Indian origin (22%). Interestingly, Mamu-B01 (26% animals) was associated with lower immune responses and higher viral loads. Another allele, A08 was also predominantly present in 37% of the animals in this study. We observed higher viral replication in individual SIV-infected rhesus monkeys that did not demonstrate strong cellular immune responses. The results are important for understanding SIV disease progression in different MHC Mamu alleles and also for improving the interpretation and quality of pre-clinical studies in rhesus monkeys.
Similar articles
-
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.J Virol. 2005 Oct;79(19):12321-31. doi: 10.1128/JVI.79.19.12321-12331.2005. J Virol. 2005. PMID: 16160159 Free PMC article.
-
CD4+ CCR5+ T-cell dynamics during simian immunodeficiency virus infection of Chinese rhesus macaques.J Virol. 2007 Dec;81(24):13865-75. doi: 10.1128/JVI.00452-07. Epub 2007 Sep 26. J Virol. 2007. PMID: 17898067 Free PMC article.
-
Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment.Virology. 2001 Jan 5;279(1):221-32. doi: 10.1006/viro.2000.0720. Virology. 2001. PMID: 11145904
-
Apoptosis in SIV infection.Cell Death Differ. 2005 Aug;12 Suppl 1:979-90. doi: 10.1038/sj.cdd.4401600. Cell Death Differ. 2005. PMID: 15818408 Review.
-
Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments.AIDS Rev. 2005 Apr-Jun;7(2):67-83. AIDS Rev. 2005. PMID: 16092501 Review.
Cited by
-
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18648-53. doi: 10.1073/pnas.0709198104. Epub 2007 Nov 13. Proc Natl Acad Sci U S A. 2007. PMID: 18000037 Free PMC article.
-
With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus.J Virol. 2008 Nov;82(22):11181-96. doi: 10.1128/JVI.01433-08. Epub 2008 Sep 10. J Virol. 2008. PMID: 18787003 Free PMC article.
-
Preclinical evaluation of HIV eradication strategies in the simian immunodeficiency virus-infected rhesus macaque: a pilot study testing inhibition of indoleamine 2,3-dioxygenase.AIDS Res Hum Retroviruses. 2013 Feb;29(2):207-14. doi: 10.1089/AID.2012.0162. Epub 2012 Oct 9. AIDS Res Hum Retroviruses. 2013. PMID: 22924680 Free PMC article.
-
A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: dose-response curve slope strongly influences class-specific inhibitory potential.J Virol. 2012 Oct;86(20):11368-72. doi: 10.1128/JVI.01563-12. Epub 2012 Aug 8. J Virol. 2012. PMID: 22875968 Free PMC article.
-
A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.J Virol. 2009 Sep;83(18):9247-57. doi: 10.1128/JVI.00840-09. Epub 2009 Jul 1. J Virol. 2009. PMID: 19570871 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials